Metformina Tarbis

Metformin Hydrochloride, the active ingredient in Metformina Tarbis, is a biguanide presented as an oral tablet for oral use. It lowers elevated blood glucose by reducing hepatic glucose output and enhancing peripheral insulin sensitivity, and is indicated for adults with type 2 diabetes mellitus.

GNH USA supplies Metformina Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with European Union pharmaceutical standards.

Metformina Tarbis is a biguanide oral antidiabetic used to manage disorders of glucose metabolism.

- Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial glucose levels. - Prediabetes (impaired glucose tolerance): delays progression to overt diabetes when combined with lifestyle measures. - Polycystic ovary syndrome (off‑label): reduces insulin resistance and may help restore ovulatory cycles.

Metformina Tarbis may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite. - Diarrhea: loose stools occurring especially during treatment initiation. - Metallic taste: transient alteration in taste perception. - Weight loss: modest reduction in body weight over time. - Vitamin B12 deficiency: decreased absorption with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening accumulation of lactate, especially in renal impairment. - Severe hypoglycaemia: when combined with insulin or secretagogues. - Hepatic failure: rare cases of liver dysfunction. - Allergic reactions: rash, pruritus, or angioedema. - Metabolic acidosis: uncommon but serious acid‑base disturbance.

Metformina Tarbis requires careful patient assessment and monitoring to minimise risks.

- Renal function: assess eGFR before initiation and periodically thereafter. - Hepatic disease: avoid in patients with severe liver impairment. - Cardiac failure: use with caution in decompensated heart failure. - Alcohol consumption: limit intake to reduce risk of lactic acidosis. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Metformina Tarbis can interact with several medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - Iodinated contrast media: may precipitate acute renal failure and lactic acidosis. - Cimetidine: can increase metformin plasma concentrations. - Alcohol: potentiates risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycaemia. - Thiazide diuretics: can attenuate glucose‑lowering effect. - ACE inhibitors or ARBs: monitor renal function and electrolytes. - Digoxin: may require dose adjustment due to altered renal clearance.